Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacteria

NESS ZIONA, Israel--(BUSINESS WIRE)-- Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

The trial was designed to evaluate the safety, tolerability and pharmacokinetics of AB103. It was a double blind, placebo controlled study that included 25 healthy volunteers receiving escalating single doses of AB103. The study was conducted at the University of Maryland in Baltimore, US.
AB103 was safe and well tolerated without any significant drug-related adverse events. Ex vivo analysis has demonstrated that AB103 does not alter the normal immune response. PK analysis indicated a dose proportional response in all kinetic parameters.

"This is a major milestone for Atox Bio and we look forward to continuing the development of AB103" stated Dan Teleman, Atox Bio's CEO. "Atox Bio is now working diligently to initiate a phase 2 proof of concept study in necrotizing soft tissue infections, a severe and life threading infection”.

Alan S. Cross, M.D., Professor of Medicine at University of Maryland in Baltimore, Center for Vaccine Development, and the study’s Principal Investigator stated that "AB103was extremely well tolerated by the subjects at every dose tested. The subject could not tell when the drug was being infused".

AB103, a novel immunomodulator, offers a unique approach in the treatment of infectious diseases by modulating but not inhibiting the host immune system. This approach of targeting the host immune response rather than the pathogen precludes the rapid generation of drug resistance and provides a multisystem solution for bacterial infections with broad-spectrum coverage, independent of pathogen type.

The phase 1 was supported by a grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) foundation.

About Atox Bio
Established in 2003 by Prof. Raymond Kaempfer, Dr. Gila Arad from the faculty of Medicine and Yissum, the technology transfer company of the Hebrew University of Jerusalem, Atox Bio is a clinical stage biotechnology company that develops peptides and small molecules therapeutics for diseases mediated by an excessive inflammatory response.
Atox Bio focuses on novel modulators that act broadly to attenuate excessive cytokine responses, with therapeutic applications ranging from infectious to inflammatory/autoimmune diseases. These applications represent areas with major unmet medical need.
For more information, please visit http://www.atoxbio.com



CONTACT:

Atox Bio
Dan Teleman - CEO
Tel: +972-8-648-4111
E-mail: [email protected]

KEYWORDS:   United States  North America  Maryland  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.